8-K: Dyadic International Faces Nasdaq Delisting Threat

Dyadic International received a notification from Nasdaq that could lead to the delisting of its securities due to non-compliance with minimum bid price and continued listing standards.

Summary

• Dyadic International, Inc. received a notification from Nasdaq on June 18, 2026, indicating a potential delisting of its securities.
• The primary reason cited is the failure to comply with Nasdaq Listing Rule 5450(a)(1) (Bid Price Rule), requiring a minimum bid price of $1.00 per share.
• The company had until June 17, 2026, to regain compliance but did not meet this deadline.
• Additionally, Dyadic failed to meet the conditions for an extended 180-day compliance period, which required a shareholders' equity of at least $5 million as of June 17, 2026.
• The company also failed to meet separate Nasdaq Listing Rule 5550(b) (Continued Listing Standards), which require meeting minimum conditions such as $2.5 million in shareholders' equity, $35 million in market value of listed securities, or $500,000 in net income from continuing operations.
• Dyadic plans to request a hearing before an independent Nasdaq hearings panel to appeal the delisting decision.
• The company may seek an extension from the panel to regain compliance, with the maximum possible extension running until December 15, 2026.
• There is no assurance that the company will regain compliance or that the Nasdaq panel will grant an extension or avoid delisting.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the immediate threat of delisting, which poses significant risks to the company's operations and future funding.

Positives

• The company plans to request a hearing before an independent Nasdaq hearings panel, which automatically stays any suspension or delisting action until a decision is made.
• Dyadic may determine to take steps to cure the deficiencies prior to the hearing date.
• The company may seek an extension from the Nasdaq panel to regain compliance.

Negatives

• Received notification from Nasdaq that could result in delisting of securities.
• Failed to comply with the minimum bid price rule ($1.00 per share) by the June 17, 2026 deadline.
• Did not meet the conditions for an extended compliance period, specifically the shareholders' equity requirement of at least $5 million as of June 17, 2026.
• Failed to meet continued listing standards, including minimum shareholders' equity, market value of listed securities, or net income from continuing operations.
• The failure to meet listing standards could adversely affect the liquidity and market price of its common stock.
• Potential negative impact on the company's ability to obtain sufficient additional capital to fund operations and continue as a going concern.

Risks

• Failure to comply with Nasdaq listing standards could lead to delisting.
• Delisting would adversely affect the liquidity and market price of common stock.
• Delisting could hinder the company's ability to obtain sufficient additional capital to fund operations.
• Risk of not being able to operate as a going concern if capital needs are not met.
• The company has a history of net losses.
• Market and regulatory acceptance of its protein production platforms and other technologies.
• Failure to commercialize its microbial protein production platforms or other technologies.
• Competition from alternative technologies.

Future Outlook

The company is pursuing a hearing with the Nasdaq panel and may seek an extension to regain compliance with listing standards. There is uncertainty regarding the outcome of the hearing and the ability to meet compliance requirements by the potential December 15, 2026 deadline.

Management Comments

• The Company plans to request a hearing before an independent Nasdaq hearings panel.
• The Company may determine to take steps to cure the deficiencies under the Bid Price Rule and the Continuing Listing Standards prior to the date of the hearing.
• The Company may determine to seek at the Panel, subject to the Panels discretion, an extension to regain compliance with the Bid Price Rule and the Continued Listing Standards.

Industry Context

StockSavvy.ai notes that Nasdaq delisting proceedings are a significant concern for companies, particularly those in growth or development stages, as it can severely impact access to capital and investor confidence. Maintaining listing standards is crucial for market liquidity and valuation.

Stakeholder Impact

• Shareholders: Potential adverse impact on stock liquidity and market price, and uncertainty regarding continued listing.
• Creditors: Potential difficulty for the company to obtain additional capital, impacting its ability to meet financial obligations.
• Employees: Uncertainty regarding the company's future operations and financial stability.
• Suppliers: Potential concerns about the company's ability to continue operations and meet payment obligations.

Next Steps

• Request a hearing before an independent Nasdaq hearings panel.
• Potentially take steps to cure deficiencies under the Bid Price Rule and Continuing Listing Standards.
• Potentially seek an extension from the Nasdaq panel to regain compliance.

Key Dates

Recommendation

The filing indicates a significant risk of delisting, which could negatively impact the stock price and liquidity. However, the company is actively pursuing a hearing and potential extensions. Investors should hold positions to observe the outcome of the Nasdaq panel's decision and the company's compliance efforts, while being aware of the heightened risk.

Keywords

Nasdaq delisting, Bid Price Rule, Continued Listing Standards, Dyadic International, SEC filing, Form 8-K, compliance, securities